Retrieve available abstracts of 61 articles: HTML format
Single Articles
June 2025
BARAGATTI M, Abdoullah B, Gomez N, Ayhan N, et al Seroepidemiological Reconstruction of Long-term Rift Valley Fever Virus
Circulation in Nouakchott, Mauritania.
J Infect Dis. 2025;231:e853-e861. PubMedAbstract available
May 2025
GRANTZ KH, Anantharam R, Kandathil AJ, Quinn J, et al Multiple approaches to genetic sequencing to identify hepatitis C virus
reinfection among people who inject drugs.
J Infect Dis. 2025 May 15:jiaf235. doi: 10.1093. PubMedAbstract available
April 2025
NDOW G, Bangura R, Vo-Quang E, Touray F, et al Residual risk of hepatitis B virus (HBV) mother-to-child transmission and gaps in
HBV care cascades among pregnant women in The Gambia: the INFANT-B study.
J Infect Dis. 2025 Apr 30:jiaf214. doi: 10.1093. PubMedAbstract available
March 2025
PAUL RC, Gidding HF, Nazneen A, Banik KC, et al Population-based estimates of hepatitis E virus associated mortality in
Bangladesh.
J Infect Dis. 2025 Mar 13:jiaf134. doi: 10.1093. PubMedAbstract available
DOYLE TJ, Buck BH, Locksmith TJ, McGruder-Rawson BM, et al Genomic epidemiology of resurgent hepatitis A in Florida, 2018-2022.
J Infect Dis. 2025 Mar 11:jiaf127. doi: 10.1093. PubMedAbstract available
February 2025
GONZALEZ-SERNA A, Corma-Gomez A, Cano M, Ricardo RS, et al Influence of Cellular Aging on Liver Stiffness in HCV Patients Achieving
Sustained Viral Response.
J Infect Dis. 2025 Feb 19:jiaf087. doi: 10.1093. PubMedAbstract available
YANG XY, Li XD, Wu BY, Yang Q, et al A Model to Identify Grey-Zone Patients with Chronic Hepatitis B Requiring
Antiviral Therapy: A Multicentre, Retrospective Study.
J Infect Dis. 2025 Feb 17:jiaf070. doi: 10.1093. PubMedAbstract available
January 2025
SUN Y, Chen Q, Liu Y, Jiao M, et al Decanoylcarnitine improves liver mitochondrial dysfunction in hepatitis B virus
infection by enhancing fatty acid beta-oxidation.
J Infect Dis. 2025 Jan 8:jiaf014. doi: 10.1093. PubMedAbstract available
SUSPENE R, Caval V, Khalfi P, Pitre E, et al Cobalt chloride-mimicked hepatocyte cell hypoxia induces TREX1 leading to
Hepatitis B virus restriction.
J Infect Dis. 2025 Jan 7:jiaf002. doi: 10.1093. PubMedAbstract available
December 2024
ZHANG X, Nguyen VH, Kam LY, Barnett SD, et al Risk Stratification of Metabolic Risk Factors and Statin Use Associated With
Liver and Nonliver Outcomes in Chronic Hepatitis B.
J Infect Dis. 2024 Dec 12:jiae522. doi: 10.1093. PubMedAbstract available
WANG J, Genberg BL, Feder K, Kirk GD, et al Impact of pandemic-induced service disruptions and behavioral changes on HCV and
HIV transmission amongst people who inject drugs: a modeling study.
J Infect Dis. 2024 Dec 6:jiae599. doi: 10.1093. PubMedAbstract available
SACHITHANANDHAM J, Leep-Lazar J, Quinn J, Bowden K, et al Direct acting antivirals eradicate HCV from the liver quickly in people with HIV
but do not fully reverse immune activation.
J Infect Dis. 2024 Dec 4:jiae598. doi: 10.1093. PubMedAbstract available
October 2024
TERRAULT NA, Sterling R, Lok AS, Ghany MG, et al HBV RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of
Nucleos(t)ide Analogue Withdrawal.
J Infect Dis. 2024 Oct 30:jiae541. doi: 10.1093. PubMedAbstract available
TRUSCELLO E, Wang S, Young J, Sebastiani G, et al Changes in hepatic steatosis before and after direct acting antiviral treatment
in people living with HIV and Hepatitis C coinfection.
J Infect Dis. 2024 Oct 17:jiae487. doi: 10.1093. PubMedAbstract available
LU Y, Xin J, Liang X, Luo J, et al Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of
Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.
J Infect Dis. 2024;230:957-969. PubMedAbstract available
YAO T, Li Y, Zhang Y, Sun Y, et al Immunogenicity, safety, and persistence induced by triple- and standard-strength
four-dose hepatitis B vaccination regimens in hemodialysis patients: A
multicenter, randomized, parallel-controlled trial in Six cities in Shanxi
Province.
J Infect Dis. 2024 Oct 8:jiae494. doi: 10.1093. PubMedAbstract available
July 2024
HORN EK, Herrera-Restrepo O, Acosta AM, Simon A, et al The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes,
Economic Costs, and Management Strategies.
J Infect Dis. 2024;230:e199-e218. PubMedAbstract available
NAKAYA Y, Onomura D, Hoshi Y, Yamagata T, et al Establishment of a hepatitis B virus reporter system harboring a HiBiT-tag in the
PreS2 region.
J Infect Dis. 2024 Jul 11:jiae353. doi: 10.1093. PubMedAbstract available
YAO Z, Gu Y, Lai X, Yang M, et al Trajectories of serum HBsAg during treatment and association with HBsAg loss in
children with HBeAg-positive chronic hepatitis B: a latent class trajectory
analysis.
J Infect Dis. 2024 Jul 5:jiae349. doi: 10.1093. PubMedAbstract available
Correction to: Antibody Levels and Protection After Hepatitis B Vaccine: Results
of a 30-Year Follow-up Study and Response to a Booster Dose.
J Infect Dis. 2024 Jul 3:jiae336. doi: 10.1093. PubMed
June 2024
BALAGOPAL A, Thio CL Hepatitis B surface antigen loss: what does integration have to do with a
functional HBV cure?
J Infect Dis. 2024 Jun 24:jiae327. doi: 10.1093. PubMed
OSMANI Z, Beudeker BJB, Groothuismink ZMA, de Knegt RJ, et al B cell activation gene signature in blood and liver of HBeAg+ immune active
chronic hepatitis B patients.
J Infect Dis. 2024 Jun 7:jiae280. doi: 10.1093. PubMedAbstract available
May 2024
GRUDDA T, Thomas DL, Kirk GD, Mehta SH, et al Hepatitis B virus DNA and RNA persist in liver after serologic recovery in
persons with hepatitis C virus.
J Infect Dis. 2024 May 23:jiae248. doi: 10.1093. PubMedAbstract available
MBISA JL, Lapp Z, Bibby DF, Phillips LT, et al Identification of two novel subtypes of hepatitis C virus genotype 8 and a
potential new genotype successfully treated with direct acting antivirals.
J Infect Dis. 2024 May 8:jiae253. doi: 10.1093. PubMedAbstract available
April 2024
SELVAMANI SP, Khan A, Tay ESE, Garvey M, et al Hepatitis B virus and hepatitis C virus affect mitochondrial function through
different metabolic pathways, explaining virus-specific clinical features of
chronic hepatitis.
J Infect Dis. 2024 Apr 24:jiae210. doi: 10.1093. PubMedAbstract available
BEGRE L, Boyd A, Plissonnier ML, Testoni B, et al Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons
with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.
J Infect Dis. 2024 Apr 16:jiae189. doi: 10.1093. PubMedAbstract available
SCHMIDT S, Mengistu M, Daffis S, Ahmadi-Erber S, et al Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional
Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High
Anti-Hepatitis B Surface Antigen Titers.
J Infect Dis. 2024;229:1077-1087. PubMedAbstract available
March 2024
WHITTAKER R, Midtbo JE, Klovstad H Monitoring progress towards the elimination of hepatitis C as a public health
threat in Norway: a modelling study among people who inject drugs and immigrants.
J Infect Dis. 2024 Mar 27:jiae147. doi: 10.1093. PubMedAbstract available
KAO CM, Rostad CA, Nolan LE, Peters E, et al A Phase 1, Double-blinded, Placebo-Controlled Clinical Trial to Evaluate the
Safety and Immunogenicity of HEV-239 (Hecolin(R)) Vaccine in Healthy US Adults.
J Infect Dis. 2024 Mar 27:jiae148. doi: 10.1093. PubMedAbstract available
KAMILI S, Wester C Advancing diagnosis of current HCV infection: A key to hepatitis C elimination in
the United States.
J Infect Dis. 2024 Mar 11:jiae127. doi: 10.1093. PubMedAbstract available
HESTERMAN MC, Fallon BS, Lynch KM, Weller ML, et al Growing Awareness: Limited Testing and Screening Bias for Hepatitis Delta Virus
in Utah 2000-2021.
J Infect Dis. 2024 Mar 8:jiae023. doi: 10.1093. PubMedAbstract available
ASLANIKASHVILI A, Rylander C, Manjavidze T, Gamkrelidze A, et al Relationship between hepatitis C infection and treatment status and
COVID-19-related hospitalizations in Georgia.
J Infect Dis. 2024 Mar 1:jiae103. doi: 10.1093. PubMedAbstract available
February 2024
HORN EK, Herrera-Restrepo O, Acosta AM, Simon A, et al The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes,
Economic Costs, and Management Strategies.
J Infect Dis. 2024 Feb 28:jiae087. doi: 10.1093. PubMedAbstract available
TU T, Ajoyan H, Nur Umami R, Veeraraghavan V, et al Inhibition of cellular factor TM6SF2 suppresses secretion pathways of Hepatitis
B, Hepatitis C and Hepatitis D viruses.
J Infect Dis. 2024 Feb 26:jiae098. doi: 10.1093. PubMedAbstract available
COLLAZOS J, Asensi V Non-invasive liver fibrosis markers in the evaluation of fibrosis regression
after direct-acting antiviral (DAA) therapy.
J Infect Dis. 2024 Feb 23:jiae095. doi: 10.1093. PubMed
MUSONDA T, Wallace MS, Patel H, Martin OP, et al New window into hepatitis B in Africa: Liver sampling combined with single cell
omics enables deep and longitudinal assessment of intrahepatic immunity in
Zambia.
J Infect Dis. 2024 Feb 9:jiae054. doi: 10.1093. PubMedAbstract available
January 2024
RINGLANDER J, Stromberg LG, Stenback JB, Andersson ME, et al Enrichment reveals extensive integration of hepatitis B virus DNA in hepatitis
delta-infected patients.
J Infect Dis. 2024 Jan 25:jiae045. doi: 10.1093. PubMedAbstract available
October 2023
IVANOVA REIPOLD E, Shilton S, Donolato M, Fernandez Suarez M, et al Molecular point of care testing for hepatitis C: available technologies, pipeline
and promising future directions.
J Infect Dis. 2023 Oct 28:jiad463. doi: 10.1093. PubMedAbstract available
FELD JJ What is needed to move toward single-step diagnosis of current HCV infection?
J Infect Dis. 2023 Oct 13:jiad453. doi: 10.1093. PubMedAbstract available
FALADE-NWULIA O, Lesko CR, Fojo AT, Keruly JC, et al Hepatitis C treatment in people living with HIV: Potential to eliminate disease
and disparity.
J Infect Dis. 2023 Oct 5:jiad433. doi: 10.1093. PubMedAbstract available
September 2023
FRICKER GP, Ghany MG, Mera J, Pinsky BA, et al Tools Needed to Support Same-day Diagnosis and Treatment of Current Hepatitis C
Infection.
J Infect Dis. 2023 Sep 22:jiad177. doi: 10.1093. PubMedAbstract available
CARTWRIGHT EJ, Patel PR Opportunities for enhanced prevention and control of hepatitis C through improved
screening and testing efforts.
J Infect Dis. 2023 Sep 22:jiad199. doi: 10.1093. PubMedAbstract available
JOHNSON LN, Gaynor AM, Wroblewski K, Buss SN, et al Maximizing Reflexive HCV RNA Testing of HCV Antibody-Reactive Samples Within
United States Public Health Laboratories.
J Infect Dis. 2023 Sep 22:jiad191. doi: 10.1093. PubMedAbstract available
TERRAULT N Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening
and Diagnosis.
J Infect Dis. 2023 Sep 22:jiad299. doi: 10.1093. PubMedAbstract available
PAGE K, Feinberg J What Hepatitis C (HCV) diagnostic tools are needed to advance diagnosis of
current HCV infection in outreach settings and in a non-clinical setting?
J Infect Dis. 2023 Sep 22:jiad269. doi: 10.1093. PubMedAbstract available
HANDANAGIC S, Shadaker S, Drobeniuc J, Tsereteli M, et al Lessons learned from global hepatitis C elimination programs.
J Infect Dis. 2023 Sep 22:jiad198. doi: 10.1093. PubMedAbstract available
LOU S, Wang J, Chen J, Xie H, et al The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the
Identification of ALPK1 P660L Variant for Predicting Response to Pegylated
Interferon alpha Therapy.
J Infect Dis. 2023;228:694-703. PubMedAbstract available
CHIEN RN, Lu SN, Hui-Min Wu G, Yang WW, et al Policy and Strategy for Hepatitis C Virus Elimination at the National Level:
Experience in Taiwan.
J Infect Dis. 2023;228. PubMedAbstract available
KONDILI LA, Craxi L, Nava F, Babudieri S, et al From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis
C Virus Elimination in Italy.
J Infect Dis. 2023;228. PubMedAbstract available
AARON A, Zhong H, Hiebert L, Zhuo Y, et al Hepatitis C Elimination in Moldova Is Feasible and Cost-Saving: A Modeling Study.
J Infect Dis. 2023;228. PubMedAbstract available
QURESHI H, Mahmood H, Sabry A, Hermez J, et al Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
J Infect Dis. 2023;228. PubMedAbstract available
WASITTHANKASEM R, Wanlapakorn N, Pimsing N, Posuwan N, et al Simplified Test-to-Treat Strategy for Hepatitis C in Thailand: The Phetchabun
Model.
J Infect Dis. 2023;228. PubMedAbstract available
NJUGUNA HN, Hiebert L, Harris A, Morgan RL, et al An Assessment of National Strategic Action Plans for Viral Hepatitis Elimination,
2016-2021.
J Infect Dis. 2023;228. PubMedAbstract available
PRZYBYSZEWSKI EM, Chung RT Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After
Hepatitis C Virus Eradication.
J Infect Dis. 2023;228. PubMedAbstract available
HUANG CF, Chen GJ, Hung CC, Yu ML, et al HCV Microelimination for High-risk Special Populations.
J Infect Dis. 2023;228. PubMedAbstract available
ADDA D, James C, Peck R, Ali M, et al The Role of Nonprofit and Nongovernmental Organizations and People With Viral
Hepatitis on the Path Toward Hepatitis C Virus Elimination.
J Infect Dis. 2023;228. PubMedAbstract available
UMUTESI J, Yu ML, Lesi O, Ward JW, et al Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan
Africa.
J Infect Dis. 2023;228. PubMedAbstract available
SPAULDING AC, Kennedy SS, Osei J, Sidibeh E, et al Estimates of Hepatitis C Seroprevalence and Viremia in State Prison Populations
in the United States.
J Infect Dis. 2023;228. PubMedAbstract available
Correction to: Evidence of Residual Ongoing Viral Replication in Chronic
Hepatitis B Patients Successfully Treated With Nucleos(t)ide Analogues.
J Infect Dis. 2023 Sep 7:jiad376. doi: 10.1093. PubMed
May 2023
THIO CL, Taddese M, Saad Y, Zambo K, et al HBeAg-negative single hepatocyte analysis shows transcriptional silencing and
slow decay of infected cells with treatment.
J Infect Dis. 2023 May 2:jiad124. doi: 10.1093. PubMedAbstract available